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INTRODUCTION 
 Nephroblastoma, or Wilms’ tumor, is an embryonal   tumor that 
develops from remnants of immature kidney. It is the most common renal 
tumour of childhood. 
NWTS-5 protocol 
 Stage I: The tumor is limited to the kidney and was completely 
excised. The renal capsule has an intact outer surface. The tumor was not 
ruptured or biopsied prior to removal (fine-needle aspiration biopsies are 
excluded from this restriction). The vessels of the renal sinus are not 
involved. There is no evidence of tumor at or beyond the margins of 
resection. 
 Stage II: The tumor extends beyond the kidney, but was completely 
excised. There may be regional extension of tumor (i.e. penetration of the 
renal capsule or extensive invasion of the renal sinus). The blood vessels 
outside the renal parenchyma, including those of the renal sinus, may 
contain tumor. The tumor was biopsied (except for fine-needle 
aspiration), or there was spillage of tumor before or during surgery that is 
confined to the flank, and does not involve the peritoneal surface. There 
must be no evidence of tumor at or beyond the margins of resection. 
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 Stage III: Residual non-hematogenous tumor is present, and 
confined to the abdomen. Any one of the following may occur:  
(1)  Lymph nodes within the abdomen or pelvis are found to be 
 involved by tumor (renal hilar, para-aortic, or beyond). (Lymph 
 node involvement in the thorax, or other extra-abdominal sites 
 would be a criterion for stage IV.)  
(2)  The tumor has penetrated through the peritoneal surface.  
(3)  Tumor implants are found on the peritoneal surface.  
(4)  Gross or microscopic tumor remains postoperatively (e.g. tumor 
cells are found at the margin of surgical resection on microscopic 
examination). (5) The tumor is not completely resectable because 
of local infiltration into vital structures. (6) Tumor spill not 
confined to the flank occurred either before or during surgery. 
 Stage IV: Hematogenous metastases (lung, liver, bone, brain, etc.), 
or lymph node metastases outside the abdominopelvic region are present. 
 Stage V: Bilateral renal involvement is present at diagnosis. An 
attempt should be made to stage each side according to the above criteria 
on the  basis of the extent of disease prior to biopsy or  treatment.  
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AIM OF THE STUDY 
 Our aim is to study the long term outcome in  156  children  with 
Wilms’ tumor from december1999 - december 2009 in ICH . 
 To analyze long term outcome in wilms tumour in perplex 
situations as double moiety, wilms with atrial thrombi,  wilms in 
syndromic variety & bilateral Wilms’, wilms in horseshoe kidney 
and extrarenal wilms 
 Our long term follow-up included time of menarche, skeletal 
growth, hyper tension , cardio toxicity due to usage of adriamycin   
& effects  of  radiotherapy. 
 To analyze the time of resolution  of IVC thrombus  and effect  of 
neo adjuvant  therapy in horseshoe kidney, solitary kidney, 
bilateral   wilms  tumour, large tumour ,distant metastasis. 
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REVIEW  OF LITERATURE  
National Wilms’ Tumor Study Group 
 The first two NWTSG studies, NWTS-1(1969–1973) and NWTS-2 
(1974–1978), showed that postoperative local irradiation was unnecessary 
for group I patients.96,97 The combination of vincristine  (VCR) and 
dactinomycin (AMD) was noted to be more effective than the use of 
either drug alone,  and the addition of doxorubicin (DOX) improved 
survival for higher-stage patients. Important findings  of NWTS-1 and -2 
were identification of unfavourable histologic features and other 
prognostic factors that allowed refinement of the staging system, 
stratifying  patients into high-risk and low-risk treatment  groups.18 It was 
recognized that the presence of  lymph node metastases had an adverse 
outcome on survival.16,17 Children with lymph node metastases as well as 
those with diffuse tumor spill were found to be at increased risk of 
abdominal relapse. Therefore, such patients were from then on classified  
as having  stage III  disease  and given  whole abdominal  irradiation. 
These findings  were incorporated  into design of NWTS -3 to try and 
decrease the intensity  of therapy   for majority  of low risk patients. 
In NWTS-3 (1979–1986), patients with stage I, FH Wilms’ tumor 
were treated successfully with  either a 10- or 18-week regimen of VCR 
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and AMD. This considerably decreased the amount of  chemotherapy 
administered and the total duration of treatment. The 4-year relapse-free 
survival was 89%, and the overall survival was 95.6%. Stage II FH 
patients treated with AMD and VCR without postoperative XRT had an 
equivalent survival (4 - year overall survival of 91.1%) to patients who 
received  the same treatment plus DOX with or without XRT. This 
demonstrated that the cardiotoxic drug DOX is not necessary for the 
successful treatment of this group of patients. This also demonstrated that 
XRT   could now be omitted for the majority of childrenwith Wilms’ 
tumor. for stage III FH patients, 10.8Gy of abdominal irradiation was 
shown to be as effective as 20 Gy in preventing abdominal relapse if 
DOX  was added to VCR and AMD. The 4-year relapse-free survival for 
stage III patients was 82% in NWTS-3  and  the 4-year overall survival 
was 90.9%. 
 Patients with stage IV FH tumors received abdominal (local)  
irradiation based on the local tumor stage. In addition, they all received 
12 Gy to both lungs. In combination with VCR, AMD, and DOX, the  
4-year relapse-free survival was 79% and the overall survival was 80.9%. 
There was no statistically significant  improvement in survival when 
cyclophosphamide was added to the three-drug regimen. 
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 The goals of NWTS-4 (1986–1994) were to continue improving 
treatment results while decreasing the cost of therapy through 
modification of the schedule of drug administration. ‘Pulse-intensive’ 
chemotherapy  regimens, employing single doses of AMDand DOX, 
were compared with regimens using  divided doses of the drugs. Pulse-
intensive regimens  utilized simultaneous administration of agents at less 
frequent intervals to decrease the number of clinic visits and hence the 
cost of cancer treatment. In addition, treatment durations of 
approximately 6 and 15 months were compared in patients with stages II–
IVFH tumors. NWTS-4 demonstrated that, while the  administered drug 
dose–intensity was greater on pulse-intensive regimens, these regimens 
produce less  hematologic toxicity than the standard regimens.19 Patients 
treated with pulse-intensive regimens achieved equivalent survival 
compared with those treated with standard chemotherapy 
regimens.20Treatment with 6 months of chemotherapy was as effective 
as 15 months. 
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 Children with anaplastic Wilms’ tumors were randomized  in 
NWTS-3 and NWTS-4 to receive VCR,AMD, DOX, or those three drugs 
with the addition of cyclophosphamide. The results were analyzed after 
the tumors were reclassified using the criteria of Fariaet al.63 There was 
no difference in outcome between the regimens for children with focal 
anaplasia, who  had a prognosis similar to that for favorable histology  
patients.21 For stage II–IV diffuse anaplasia, the addition of 
cyclophosphamide to the three-drug regimen improved the 4-year 
relapse-free survival (27.2%vs 54.8%). 
 Treatment of patients with stage I or II FH tumors, and stage I 
anaplastic Wilms’ tumor was the same. They received a pulse-intensive 
regimen of VCR and AMD for 18weeks. Patients with stage III FH and 
stage II–III  focal anaplasia were treated with AMD, VCR, and DOX, and 
10.8 Gy XRT. Patients with stage IV FH tumors received abdominal 
irradiation based on the local tumor stage and 12 Gy to both lungs. 
NWTS-5 was a single-arm therapeutic trial without any randomization 
for therapy. Prospective collection of information regarding biologic 
features of the tumors was part of this study. A collection of banked 
tumor specimens is available to evaluate new prognostic factors that may 
be identified in the future.  
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 Most importantly, the clinical outcome is available for patients for 
whom there are banked specimens. One of the primary goals of the study 
was to verify the preliminary   findings that loss of heterozygosity (LOH) 
for chromosomes 16q and 1p is useful in identifying patients at increased 
risk for relapse and death. Among patients with stage I–II FH tumors, the 
relative risk (RR) of relapse and death were increased for LOH 1p only 
(RR = 2.2 for relapse; RR = 4.0 for death), for LOH 16q only (RR = 1.9 
and RR = 1.4),and for LOH for both regions (RR = 2.9 and RR = 4.3) in 
comparison with patients lacking LOH at either locus.52 The risks of 
relapse and death for patients with stage III–IV FH tumors were increased 
only with LOH for both regions (RR = 2.4 and RR = 2.7). These results 
demonstrate that LOH for these chromosomal regions can now be used as 
an independent prognostic factor, 
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Treatment  scheme used in wilms tumour study-5 
      Radiotherapy  Chemotherapy 
Stage I and II, favorable histology                         None      Regimen 4A 
Stage I focal or diffuse anaplasia 
Stage I, favorable histology, age <2 years, tumor weight <550 g None     
Regimen EE-4A 
Stage III and IV, favorable histology                     yes      Regimen DD-4A 
Stage II–IV, focal anaplasia 
Stage II–IV, diffuse anaplasia                                 Yes        Regimen I                              
Stage I–IV clear cell sarcoma of the kidney 
Stage I–IV rhabdoid tumor of the kidney                Yes     Regimen RTK 
a 1998 modification to original protocol: 
■  Regimen EE-4A: pulse-intensive dactinomycin, vincristine (18 
weeks) 
■  Regimen DD-4A: pulse-intensive dactinomycin, vincristine, 
doxorubicin (24 weeks) 
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■  Regimen I: dactinomycin, vincristine, doxorubicin, 
cyclophosphamide, and etoposide (24 weeks) 
■  Regimen RTK: carboplatin, etoposide and cyclophosphamide  
(24 weeks) 
■  Stage IV/FH patients are given radiation based on the local tumor 
stage classified as having stage III disease and given whole 
abdominal irradiation.  These findings were incorporated into the  
design of NWTS-3 to try and decrease the intensity of therapy for 
the majority of low-risk patients. 
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HYPERFILTRATION  damage:  theory  and practice 
 After  nephrectomy,it is the normal  response of  the remaining  
kidney to hypertrophy.the stimulus   for this hypertrophic response 
follows a rapid increase in blood flow in response to contralateral 
nephrectomy. Hostetter et al drew attention to the observation that 
hyperfiltration in  remnant nephron was a potentially adverse response  
to renal ablation.Rats with subtotal renal ablation developed 
glomerulosclerosis and progressive renal damage. 
 Rats are  to more prone to develop proteinuria and reductions in 
glomerular   filtration. 
 Rate if uninephrectomy was done  in infancy versus adulthood. 
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DEMOGRAPHICS OF  WILMS IN ICH-CHENNAI 
 
 
 
 
 
 
 
 
 Number  of  wilms  patients  between  1999 -2009 :156 
Gender-slight male predominance 
Male—99    female-57 
Age at diagnosis (years) 
Most of  the children were between 1-5 years 
                  Number of children under 1year-  14 (8m,6f)                                        
                  Number of children  between 1-5-  117(70m,47f) 
                   Number of children between 6-10-23(20m,3f) 
                  Number of children more than10years-2(1m,1f) 10years 
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Initial clinical presentation 
Palpable abdominal mass                          137(91.2%)  
Gross hematuria                                         4  
Abdominal pain                                         8 
Fever                                                          6 
Nausea/vomiting                                       1 
Ascites                                                       1 
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Associated anomaly 
Beckwith-wiedemann syndrome               2                           
duplex kidney                                            2       
Congenital blindness                                 1          
WAGR                                                      1 
Horseshoe kidney                                     2 
Hypospadias                                              1 
Extra-renal wilms                                      1 
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PATHOPHYSIOLOGY 
 More than one-third of kidneys resected for Wilms’tumor contain 
precursor lesions, known as nephrogenic rests.68 Nephrogenic rests 
represent the abnormal persistence into postnatal life of embryonal 
cellsthat can produce a malignancy. Two distinct categories of 
nephrogenic rests exist, based on the position of these lesions within the 
renal lobe. Perilobar nephrogenic rests (PLNRs) are confined to the 
periphery of the renal lobe. Intralobar nephrogenic rests (ILNRs) occur 
anywhere in the kidney, including the renal sinus and collecting system. 
There are biologic differences distinguishing PLNR fromILNR (Table). 
Nephrogenic rests have a varied life and most do not form Wilms’ tumor.  
A rest can undergo maturation, sclerosis, involution, and complete 
disappearance. PLNRs have been detected in1% of kidneys in infants on 
postmortem examination; most of these rests apparently undergo 
involution.69 ILNR can become cystic and be indistinguishable  from 
renal dysplasia. Hyperplastic nephrogenic rests can produce a renal mass 
easily mistaken for a small Wilms’ tumor. Biopsy of a hyperplastic rest is 
of little value in distinguishing this lesion from a Wilms’ tumor unless the 
interface between the rest and normal  kidney  of included. Wilms’ tumor 
will have a pseudocapsule at the interface, with the normal parenchyma 
compressing  the normal elements. Neoplastic induction of cells of a 
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nephrogenic rest can produce Wilms’ tumor and  possibly other benign or 
malignant renal neoplasms.The Wilms’ tumor will have a spherical 
shape, whereas hyperplasic rests will be more elliptical orlenticular 
in shape. Magnetic resonance imaging (MRI) may be of some value in 
distinguishing between the two lesions, but this needs to be confirmed  
prospectively in large numbers of patients 
                                                    ILNR                                PLNR 
Associated                                  WAGR                 BWS 
Syndromes                                                   
                                                                         Denys–Drash                
     Hemihypertrophy 
Genitourinary   anomalies          perlman         
Median age of                            23 months                        36 months 
WAGR = Wilms’ tumor, aniridia, genitourinary, 
and retardation; BWS = Beckwith–Wiedemann 
syndrome; ILNR = intralobar nephrogenic rest; 
PLNR = perilobar nephrogenic rest. 
 Abnormal collections of blastemal cells are found in about 1%of 
kidneys on postmortem examination, yet these are found  in 
approximately 40% of kidneys removed for Wilms’ tumor  .These 
histologic abnormalities are found uniformly in the kidneys of children 
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with an inherited susceptibility to Wilms’  tumor. When multiple 
nephrogenic rests are found, or when  the presence of rests can be 
inferred, such as in multicentric or bilateral Wilms’ tumor, the condition 
is described as nephroblastomatosis.  Not all nephroblastomatoses 
develop into  Wilms’ tumor; most regress or develop into a clinically 
insignificant benign entity. Detection of these rests is challenging on 
conventional imaging, and they are found only on extensive histologic 
search. Depending on their location in the kidney, these nephrogenic rests 
are divided into intralobar rests (i.e., within the lobe of the kidney) or 
perilobar rests (i.e., at the periphery of the kidney). Perilobar nephrogenic 
rests are associated with  11p15 (WT2): Beckwith-Wiedemann syndrome 
and synchronous  bilateral Wilms’ tumor. Intralobar nephrogenic rests are 
associated with 11p13 (WT1): aniridia, Denys-Drash syndrome, 
and metachronous Wilms’ tumor . 
Overgrowth                      Non-overgrowth 
Beckwith-Wiedemann                         Denys-Drash 
Hemihypertrophy                                 WAGR 
Perlman                                                 Aniridia 
Sotos 
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PATHOLOGY OF WILMS’ TUMOR 
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PATHOLOGY OF WILMS TUMOUR 
 
 
 
 
 
 
 
  
 On gross specimen, Wilms’ tumor has a varied appearance  of 
smooth to cystic and variegated on cut section. There is no distinct 
capsule, but the surrounding mesenchyme condenses  to form a 
pseudocapsule. Occasionally, hemorrhage and necrosis are noted on gross 
specimen examination. The whole specimen is handled very carefully, 
and gross specimen examination, microscopic study, and further biologic 
studies are performed according to the protocols by SIOP 2002 in Europe 
and the American College of Pathologists in the United States.  For 
macroscopic examination, the tumor should be send to  the pathology 
department intact without formalin preservative. The examination 
includes specimen weight, tumor location, capsule invasion, renal vein 
and sinus invasion, ureter, and cut surface of the kidney if a 
heminephrectomy was performed. 
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epithelial
tubular
blastemal
We have had 154 favourable histology  
and two unfavourable in our study  
EPITHELIAL 
                 
 
 
 
TUBULAR 
 
 
 
 
BLASTEMAL 
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MANAGEMENT OF WILMS’ TUMOR 
                                                      
IVU-shows calyceal  distortion in right kidney in wilms tumour 
 
 
 
 
 
 
 A computed tomography scan of a 3.5-year-old girl who presented 
with a large abdominal mass demonstrating the characteristic findings of 
3year male child presented  
with lung secondaries and right  
kidney involved with wilms 
tumour. 
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a Wilms' tumor. The tumor mass can be seen protruding from the right 
kidney with a margin of renal parenchyma along the periphery. 
 
 
 
 
 
 
 Management consists of surgery for removal of the primary  tumor 
with the kidney (radical nephrectomy), with chemotherapy  and 
radiotherapy in some cases. The management  is guided by the NWTS 
Rhabdoid tumour with liver 
metastases  
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protocol in   ICH-CHENNAI  and in the United States and the SIOP 
protocol in Europe according to the stage of the tumor. 
Surgery 
 Radical nephrectomy for removal of the primary tumor  with the 
kidney is the mainstay of treatment. This procedure allows the removal of 
the primary tumor and accurate staging of the tumor. The usual approach 
is transperitoneal through a transverse abdominal incision, which gives 
good access to the tumor and vasculature. 
The principles of surgery are as follows: 
1.  Palpation of liver, abdomen, and para-aortic region for regional 
spread of disease 
2.  Removal of intact specimen in total 
3.  Avoidance of local spillage because these children have a sixfold 
increase in local abdominal relapse36 
4.  Nodal sampling rather than clearance because there is no added 
advantage in the long-term survival37 
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5.  Proper identification and avoidance of injury to contralateral  renal 
vessels, aorta, and iliac and superior mesenteric arteries38 
6.  Palpation of the renal vein and inferior vena cava before ligation to 
rule out thrombus.  
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PRINCIPLES OF RADICAL NEPHRO URETERECTOMY   
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 Primary Nephrectomy (NWTS) and Neoadjuvant  Chemotherapy 
Followed by Nephrectomy (SIOP)GEARHART-Pediatric  urology. 
 According to the NWTS protocol, following confirmation on 
imaging, the nephrectomy is performed enabling the collection of tissue 
for histologic diagnosis, primary removal of the tumor, and exact staging. 
This surgery is often challenging, however, in view of the tumor size and 
the need to adhere to strict principles of surgery, especially regarding 
intraoperative tumor spilling. 
 According to the SIOP protocol, after imaging of the tumor, a  
fine-needle biopsy is performed to obtain a histologic diagnosis. Under 
the same anesthesia, vascular access (Hickman line) is obtained for 
administering the  chemotherapy. After 4 weeks of chemotherapy, the 
response is assessed by repeat ultrasound scan, and nephrectomy is 
performed on week 5 or 6 (SIOP-9 2001). The potential  advantage is that 
the tumor is small, and the risk of intraoperative   spillage is reduced. 
 According to the UKW3 study group, this approach has also 
resulted in a shift toward a more advantageous stage distribution and 
reduction in therapy and late effects of doxorubicin and radiotherapy.44 
The disadvantage is that studying tumor specimen histology  after 
chemotherapy may not be the same as the NWTS protocol, especially 
nodal histology for defining postoperative chemotherapy. 
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Indications of Preoperative Chemotherapy  for Wilms’ Tumor 
(NWTS) 
 (Gearhart-50-677) primary nephrectomy is performed  according to 
the NWTS protocol, but there is a role for preoperative chemotherapy in 
patients with the following  conditions:  
1.  Inoperable tumor at the primary nephrectomy because  removal of 
surrounding organs can result in an increased  risk of surgical 
complications 
2.  Inferior vena cava thrombus, especially the suprahepatic  level, 
reducing the need for cavotomy and cardiopulmonary bypass as per 
NWTS and UKW3 trial 
3.  Bilateral tumor at the diagnosis or incidental finding, at the primary 
nephrectomy. 
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Surgical Complications 
• NWTS has reported a surgical complication rate of 11% for  
primary nephrectomy.  
• Common complications were hemorrhage and small intestinal 
obstruction. Other complications  are intussusception and damage 
to adjacent organs. 
•  The cause  of intestinal obstruction in the late postoperative period  
is mostly adhesions. Risk factors identified were higher local tumor 
stage, intravascular extension, and 
•  en bloc resection of other visceral organs 
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MANAGEMENT OF BILATERAL WILMS TUMOUR 
 Our   management in bilateral wilms tumor   includes incisional   
biopsy   and confirmation. After   confirmation ,  chemotherapy   was  
given for  6 cycles  with  Vincristine ,  pulse-intensive Actinomycin D. 
After  6 cycles  of chemotherapy, surgery   was undertaken .Out of 9  
patients,  7 patients  underwent  unilateral radical  nephrectomy   and   
2    partial  nephrectomy  Further 6 cycles of  chemotherapy  was given   
For  the  residual  lesion  in opposite   kidney,   radiotherapy   of  10.8Gy  
was  given  in  16 sittings  .Disease free survival years are less than  
2 years. 
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MATERIALS AND METHODS 
 
Patients and Methods 
 It is a combined prospective and retrospective study which 
pediatric urology OPD at the Institute of Child Health and Hospital for 
Children, Madras Medical College, Chennai. The study included patients 
with wilms, who attended the pediatric surgery  during the ten years 
period, from Jan 1, 2000 to Dec 31, 2009.  
Selection Criteria 
All  patients with renal mass, hematuria, fever, abdominal pain 
Inclusion Criteria 
All patients with wilms tumour were proven  radiologically , 
sonographically and HPE wise 
Exclusion Criteria 
- stromal  tumours as clear cell  sarcoma . 
- congenital  mesonephric hamartoma 
- rhabdoid tumour. 
- angiomyolipoma of the kidney 
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 The patients were subjected to detailed clinical examination and 
relevant investigations were performed, namely, ultrasound examination,  
IVU, +/- CECT.The treatment modalities were studied and patients were 
followed up to screen for residual lesion size, recurrences and liver and 
lung  secondaries. 
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PROFORMA 
Personal Details -  
Name     Age    Sex 
IP No. 
Address 
Date 
Clinical Symptoms 
□ Asymptomatic     □ abdominal mass   
□ Haematuria      □ anemia 
□ hypertension                □ dysuria 
□ aniridia 
Laterality  
□ U/L (Rt/Lt)  
□ B/L-  
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Investigations 
Renal Parameters  
BU/SC/SE –  
Contra-lateral Renal Status (in U/L cases and other problems) –  
U/S KUBU  Report –mass cystic or solid, presence of thrombus in IVC or 
renal vein  
IVU –  calyceal  distortion, duplex system is well seen in ivu than 
CECT 
CECT –confimative of mass lesion -  
Treatment 
□ Primary radical nephro-ureterectomy  followed by  
chemotherapy  
□ radiotherapy  for stageII,   III, IV, and V  
 
HPE Report 
  
Favorable triphasic  histology. 
Unfavorable  anaplastic  
Focal versus diffuse  anaplasia 
post-op follow up monthly f/u 
 
U/S abdomen :  look for residual and recurrent lesion and secondaries in 
liver 
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Chest xray : look for secondaries in lungs 
 
Follow-up protocol  
 
- monthly f/u  for 6months 
- 3monthly f/u  for 6visits. 
- 6monthly f/u for 2years 
- yearly f/u  till life 
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MASTER CHART  
 
Name 
Age & 
Sex F/U Stage  HPE Hpe Surgery  Chemo & RT  Last F/U 
Jerusha 2/F 14.01.03 5 B/L FH Triphasic 
PRE-OP 
CHEMO18WKS Ct&Rt L.NU.RK-N 18.3.03 
Kani 3/m 4.11.03 5 B/L FH Triphasic Partial nephrectomyB/L CT&RT residual+ 10.08.04 
Ramesh  12.11.03 5 B/L FH Triphasic neo-adjuvant CT&RT   
Sajad   5 B/L FH Triphasic neo-adjuvant CT&RT   
Vimalraj 1/M  5 B/L FH Triphasic neo-adjuvant CT&RT   
Monisha 2y6m 2007 5 B/L FH Triphasic 
l.nephroureterectomy 
&rt.debulking-610679 CT&RT  
Supraclavicular  
node+ 
Anitha 1y6m 3.04.07 5 B/L FH Triphasic neo-adjuvant CT&RT   
Veeraraj 7/m 15.11.99 5 B/L FH Triphasic 
l.nephroureterectomy 
&rt.debulking-610679 CT&RT anuria 15.4.03 
Benedictroselin- 4/m 2008 5 B/L FH Triphasic 
chemo-l.nephrouret 
erectomy-RT CT&RT   
jayasoorya 3y6m 13.6.06 2 R 
focal 
anaplasia Triphasic r.nephroureterectomy CT&RT  2009-DEC 
Sathish 3/m  2 R 
residual 
r.wt Triphasic r.nephroureterectomy CT&RT  2008-AUG 
Kanya 1y  1 R FH Triphasic metachronous WT CT&RT lung sec.  
kamatchi 8/f  4 R FH Triphasic r.nephroureterectomy CT&RT liver sec  
Dinesh 3/m 20.06.07 2 R FH Triphasic metachronous WT CT&RT ascites  
Saranya 11/f 2000TMC 4 L FH Triphasic liver sec CT&RT ascites 2006-f/u 
Ramya <1/f  1 R FH Triphasic metachronous WT CT&RT r.lung sec  
ramachandran  8/m Feb-97 3 R FH Triphasic r.nephroureterectomy CT&RT  2006-well 
Karthik 6/mm 
jan-98-
madurai 3 R FH Triphasic cystic wilms CT&RT tumour  spill 2000-AMA 
Aravind 2y6m  3 L FH Triphasic L.nephroureterectomy CT&RT   
anbarasan 1/m  1 L FH Triphasic l.nephroureterectomy    
 38
Name 
Age & 
Sex F/U Stage  HPE Hpe Surgery  Chemo & RT  Last F/U 
beula 9/f 17.10.98 1 L FH Triphasic l.nephroureterectomy CT&RT  2003 
babu 10/m  3 
Horseshoe 
kidney-03 FH Triphasic 
partial 
nephrectommmmy CT&RT  2003 
bavani 5/f  3 L FH Triphasic l.nephroureterectomy    
Elizabeth 4/f 1997 3 L FH Triphasic L.nephroureterectomy    
hakeem   1 L FH Triphasic L.nephroureterectomy   2005 
hemanathan   1 L FH Triphasic L.neprhroureterectomy   2005 
Habibunisha     8/f  1 L FH Triphasic l.nephroureterectomy    
janathnisha  
7month 7months  2 R FH Triphasic r.nephroureterectomy   2006 
jagadesh 4/m  3 R FH Triphasic r.nephroureterectomy CT&RT   
Jayaraman 2/m  1 R FH triphasic r.nephroureterectomy hemihypertrophy  2009 
jagan   1 L  triphasic r.nephroureterectomy   2003 
karthik 4/m  1 R FH triphasic r.nephroureterectomy    
kousalya 1/f  2 R FH triphasic r.nephroureterectomy    
kalaiselvi 1/f  2 L FH triphasic r.nephroureterectomy    
kavinraj 1/f 12.01.02 1 R FH triphasic r.nephroureterectomy   f/u3.08.08 
lavanya 6/f Nov-01 2 L FH triphasic l.nephroureterectomy 366277  f/u-2003 
mohaprabu 3months  3 L FH triphasic l.nephroureterectomy    
manojkum 5/m  3 L FH triphasic l.nephroureterectomy    
manirathnam   4/m  1 L FH triphasic l.nephroureterectomy    
malarvizhi 5months  2 R FH triphasic r.nephroureterectomy    
manimegalai  
1/f   2 L FH triphasic l.nephroureterectomy    
nandagopal    1/m  2 L FH triphasic l.nephroureterectomy    
nithya 9/f 5.1.99 2 L FH triphasic l.nephroureterectomy 264470   
Priya   2 R FH triphasic r.nephroureterectomy    
priyadarshini   3 L FH triphasic l.nephroureterectomy    
prescila 3y6  3 L FH triphasic l.nephrouretectomy terectomy   
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Name 
Age & 
Sex F/U Stage  HPE Hpe Surgery  Chemo & RT  Last F/U 
preethy 3y6  2 L FH triphasic l.nephroureterectomy    
sudhakar 4y6  2 L FH triphasic l.nephroureterectomy    
satyanarayan   3/m  2 R FH triphasic r.nephroureterectomy   2010-may 
Satish 3/m  3 R FH triphasic r.nephroureterectomy    
suresh 2/m  3 R FH triphasic r.nephroureterectomy CT&RT  May-10 
vijay 3/m  3 L FH triphasic l.nephroureterectomy CT&RT   
vimalraj 7months May-01 2 R FH triphasic r.nephroureterectomy half dosechemo   
vignesh 7/m   L FH triphasic l.nephroureterectomy    
vino 5/m  3 R FH triphasic r.nephroureterectomy    
vanitha 5/f Dec-00 4 R FH triphasic r.nephroureterectomy lung sec-mar.01  2003-well 
yuvarani 3/f   R FH triphasic r.nephroureterectomy    
naveenkumar   1y6m   L FH triphasic l.nephroureterectomy    
praveena 4/f  3 R FH tubullar r.nephroureterectomy    
chelladurai  1/m   3 L FH triphasic L.nephrourterectomy    
pushpakar 3/m May-02 3 L FH triphasic L.nephroureterectomy CT&RT ?cxr-sec 30.09.08 
aravind 2y6m 
f/u-
30.03.04 3 L FH triphasic l.nephroureterectomy    
ajitkumar 4/m 21.2.04 2 R FH triphasic r.nephroureterectomy    
archana 5/f 09.09.04 3 L FH triphasic l.nephrourreterectomy   Dec-09 
adinarayanan 7/m Mar-04 3 L FH triphasic l.nephroureterectomy CT&RT  Feb-10 
dilliprakash   1y3m 19.10.05 3 L FH triphasic L.nephroureterectomy CT&RT  Jan-09 
franciskennady  Jan-03 3 R FH triphasic r.nephroureterectomy CT&RT  Dec-09 
gowthami 5/f  3 R FH triphasic r.nephroureterectomy CT&RT  Apr-10 
Hemadevi   1y9m 23.03.04 2 R FH triphasic r.nephroureterectomy CT&RT  May-10 
ilakya 2/f 30.06.05 1 L FH triphasic l.nephroureterectomy defaulted   
Jayashree 1y6m 28.10.03 3 R FH triphasic r.nephroureterectomy CT&RT  Nov-09 
kavya 1y3m 2003 3 R FH epithelial r.nephroureterectomy CT&RT  Aug-09 
Kumaran 3y6m 19.10.04 3 R FH triphasic r.nephroureterectomy CT&RT   
karthik 3/m jan.05 1 R FH triphasic r.nephroureterectomy CT&RT recurrence Sep-09 
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karthik 4/m jan.05 2 R FH triphasic r.nephroureterectomy CT&RT  Oct-09 
lokesh 1O/M 21.06.05 2 R FH triphasic r.nephroureterectomy CT&RT   
sandya 4/f 2009 3 R FH triphasic r.nephroureterectomy CT&RT  Jun-09 
Manikandan     3/m 29.3.03 1 L FH triphasic L.nephroureterectomy   Nov-09 
Manikandan     3/m 19.1.04 2 L FH triphasic l.nephroureterectomy    
Meenakshi 6/F 27.03.04 3 L FH triphasic l.nephroureterectomy CT&RT  Jan-10 
nithya 9/f  3 R FH triphasic r.nephroureterectomy CT&RT   
dathathreyan   1y6m 2008 3 R FH triphasic r.nephroureterectomy   Dec-09 
Pooja 1Y1M 2008 1 L FH blastemal l.nephroureterectomy   Feb-10 
sindhu 5/m 2008 1 R FH epithelial r.nephroureterectomy   Apr-10 
reddiyama 5/f 2008 2 R FH triphasic r.nephroureterectomy CT&RT  Mar-10 
chandru 1y6m 2008 1 R FH triphasic r.nephroureterectomy   May-10 
dhanusha 4/f 2008 3 L FH triphasic l.nephroureterectomy CT&RT  Dec-09 
wahithabanu    4/f 2008 3 L FH triphasic l.nephroureterectomy   Nov-09 
abimanu 4/m 13.06.06 1 R FH triphasic r.nephroureterectomy   Jun-09 
Anitha 1y6m 3.04.07 5 b/l FH triphasic  CT&RT  lostf/u 
barath 10months 4.12.07 1 L FH triphasic l.nephroureterectomy   Aug-09 
Darshini 1y6m 10.07.07 1 R FH triphasic r.nephroureterectomy   May-10 
dinesh 10months 30.04.07 1 L FH triphasic l.nephroureterectomy   Apr-09 
dathatreyan    1y6m 24.01.08 3 R FH triphasic r.nephroureterectomy CT&RT   
gouthami 6/f Jun-04 3 R FH triphasic r.nephroureterectomy 
thrombus  not 
extracted  f/u-24.5.08 
ganesan 1y6m 26.06.06 3 R FH triphasic r.nephroureterectomy CT&RT  Sep-09 
gayathri 2y6m 11.07.06 3 L FH triphasic l.nephroureterectomy CT&RT  Oct-09 
harshavardan    4/m 10.06.06 2 R FH triphasic r.nephroureterectomy CT&RT  Jan-10 
kamesh 3y6m  3 R FH triphasic r.nephroureterectomy CT&RT  Jul-09 
kalaiselvan     6/m  3 L FH triphasic  CT&RT  lostf/u 
monisha 4y6m  3 R FH triphasic r.nephroureterectomy CT&RT   
niranjan  Mar-06 3 R FH triphasic r.nephroureterectomy CT&RT  Feb-09 
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parthiban 2y9m 19.01.06 3 L FH triphasic l.nephroureterectomy CT&RT  Aug-09 
purosathaman    5/m 18.07.06 1 R FH triphasic r.nephroureterectomy   Apr-10 
praveen 7/m  2 R FH triphasic r.nephroureterectomy CT&RT  Mar-10 
pooja 1/f 19.09.06 1 R FH triphasic r.nephroureterectomy    
pooja 11months 18.01.08 1 R FH triphasic r.nephroureterectomy    
Ravikumar 4/m 26.10.06 1 L FH triphasic L.nephroureterectomy   16.9.08 
tamilarasan 1y6m 30.12.06 2 R FH triphasic r.nephroureterectomy CT&RT   
tangamani 3/m 13.06.07 2 R FH triphasic r.nephroureterectomy local recurrence  lostf/u 
anish 11months 2008 1 L FH triphasic L.nephroureterectomy   Apr-10 
pavithra 2/f 2008 1 L FH triphasic L.nephroureterectomy cysticwilm  May-10 
mohanraj 3/m 2008 2 L FH triphasic L.nephroureterectomy CT&RT  Sep-09 
sudharsana 7/m 1.7.03 
3horse shoe 
kidney  FH triphasic L.nephroureterectomy tumour spill  f/u-23/5/06 
pushpakar 4y6m 2003 2 L FH triphasic L.nephroureterectomy CT&RT  Jul-09 
pavithra 2/f 2003 2 R FH triphasic r.nephroureterectomy CT&RT  Jun-09 
parthiban 1y6m 2003 1 L FH triphasic l.nephroureterectomy    
syedsulthana    5mon 2003 1 R FH triphasic r.nephroureterectomy    
sheela 4/f 2003 2 L FH triphasic L.nephroureterectomy ct&rt  Feb-20 
sharmila 3y6m 2004 1 R FH triphasic r.nephroureterectomy 522799 2008-well  
sundarrajan    8/m 2005 2 R UFH triphasic r.nephroureterectomy   lost f/u 
surya 5/m 2005 duplex-2 R FH triphasic r.heminephrectomy 446864 recurrence defaultedRT 
sakthivel 10months 2006 4 L FH triphasic L.nephroureterectomy   Oct-09 
Thirumalai 4/m 2006 2 L FH triphasic L.nephroureterectomy   Nov-09 
thirunavukarasu  9/m 2006 2 L FH triphasic L.nephroureterectomy   Jun-09 
thilani 5/f 2005 1 L FH triphasic L.nephroureterectomy   Sep-08 
thirumurugan  5/m 1.2.2006 3 R FH triphasic r.nephroureterectomy 524468 f/u9.9.08  
vasanthkumar   7/m Mar-06  L FH triphasic L.nephroureterectomy 506170  Sep-09 
yuvaraj 1y6m Sep-06  L FH triphasic L.nephroureterectomy   Jan-10 
yasmin 4/f Apr-06  L FH triphasic L.nephroureterectomy   Apr-09 
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hemadevi 1y9m 3.4.04 2 R FH triphasic r.nephroureterectomy   Feb-10 
lavanya 8/f 23.02.05 3 R FH triphasic r.nephroureterectomy 
lung RT-
givenf/u-15.7.08   
kaviarasan  1997  L FH triphasic L.nephroureterectomy  2008-well  
sangeetha   3 L FH triphasic L.nephroureterectomy 8yr-survival   
soubarnika  97  R FH triphasic r.nephroureterectomy 11yr-survival   
sathishkumar    R FH triphasic r.nephroureterectomy 15yr-survival   
Binnsajan 6/m 568257 2 L FH triphasic l.nephroureterectomy recurrence lung sec  
kamurunisha- 12/f  2 L FH triphasic l.nephroureterectomy hemihypertrophy  May-10 
muthumadhavan  6/m  duplex-3  FH triphasic l.nephroureterectomy    
thanusha 4/f  3 R FH triphasic 
atrial thrombus-partial 
thrombectomy    
kumaran 3y6m 473179 3 R FH triphasic l.nephroureterectomy thrombectomy  f/u2009-feb 
chaitanya 3/f  3 R FH triphasic tumor dissemination  neoadjuvani  
rohith 2/m  3 L FH triphasic l.nephroureterectomy biopsy death  
malarvizhi 5/f 674021 1 R FH triphasic r.nephroureterectomy hpe195/10   
deepika   3 L FH epithelial l.nephroureterectomy  neoadjuvant  
sudharsan 1y6m 672054  R FH triphasic r.nephroureterectomy    
deepak 2/m 674525  l FH triphasic l.nephroureterectomy    
sabarivasan- 2/m 673 2 l FH triphasic l.nephroureterectomy  
WAGR-
syndrome  
monisha 2/F 674101 4 R FH 
Rhabdomyo 
matous r.nephroureterectomy  neoadjuvant  
soundarya 6/f 673833 3 R FH 
Rhabdomy 
omatous r.nephroureterectomy ascites neoadjuvant  
aswathdevi 1y6m 676082 3 R FH 
Rabdomy 
omatous l.nephroureterectomy  neoadjuvant  
jeganbabu 4M 664680  L FH  r.nephroureterectomy    
harish 3y6m 658953 4 R FH triphasic r.nephroureterectomy lung sec death  
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nivedha 3/F  2 L FH triphasic l.nephroureterectomy   Apr-10 
alifa 9months  4 L UFH rhabdoid l.nephroureterectomy liver sec death  
senbagavel 3/m  3 R FH triphasic   neoadjuvant  
Jerusha 2/f 14.01.03 5 B/L FH Triphasic pre-op chemo18wks CT&RT l.nu.rk-N 18.3.03 
Kani 3/m 4.11.03 5 B/L FH Triphasic Partial nephrectomyB/L CT&RT residual+ 10.08.04 
Ramesh  12.11.03 5 B/L FH Triphasic neo-adjuvant CT&RT   
Sajad   5 B/L FH Triphasic neo-adjuvant CT&RT   
Vimalraj 1/M  5 B/L FH Triphasic neo-adjuvant CT&RT   
Monisha 2y6m 2007 5 B/L FH Triphasic 
l.nephroureterectomy 
&rt.debulking-610679 CT&RT  
Supraclavicular  
node+ 
Anitha 1y6m 3.04.07 5 B/L FH Triphasic neo-adjuvant CT&RT   
Veeraraj 7/m 15.11.99 5 B/L FH Triphasic 
l.nephroureterectomy 
&rt.debulking-610679 CT&RT anuria 15.4.03 
Benedictroselin- 4/m 2008 5 B/L FH Triphasic 
chemo-l.nephrouret 
erectomy-RT CT&RT   
jayasoorya 3y6m 13.6.06 2 R 
focal 
anaplasia Triphasic r.nephroureterectomy CT&RT  2009-DEC 
Sathish 3/m  2 R 
residual 
r.wt Triphasic r.nephroureterectomy CT&RT  2008-AUG 
Kanya 1y  1 R FH Triphasic metachronous WT CT&RT lung sec.  
kamatchi 8/f  4 R FH Triphasic r.nephroureterectomy CT&RT liver sec  
Dinesh 3/m 20.06.07 2 R FH Triphasic metachronous WT CT&RT ascites  
Saranya 11/f 2000TMC 4 L FH Triphasic liver sec CT&RT ascites 2006-f/u 
Ramya <1/f  1 R FH Triphasic metachronous WT CT&RT r.lung sec  
ramachandran  8/m Feb-97 3 R FH Triphasic r.nephroureterectomy CT&RT  2006-well 
Karthik 6/mm 
jan-98-
madurai 3 R FH Triphasic cystic wilms CT&RT tumour  spill 2000-AMA 
Aravind 2y6m  3 L FH Triphasic L.nephroureterectomy CT&RT   
anbarasan 1/m  1 L FH Triphasic l.nephroureterectomy    
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NAME 
Age & 
sex F/U STAGE  HPE HPE Surgery  Chemo & RT  last f/u 
beula 9/f 17.10.98 1 L FH Triphasic l.nephroureterectomy CT&RT  2003 
babu 10/m  3 
Horseshoe 
kidney-03 FH Triphasic 
partial 
nephrectommmmy CT&RT  2003 
bavani 5/f  3 L FH Triphasic l.nephroureterectomy    
Elizabeth 4/f 1997 3 L FH Triphasic L.nephroureterectomy    
hakeem   1 L FH Triphasic L.nephroureterectomy   2005 
hemanathan   1 L FH Triphasic L.neprhroureterectomy   2005 
Habibunisha     8/f  1 L FH Triphasic l.nephroureterectomy    
janathnisha  
7month 7months  2 R FH Triphasic r.nephroureterectomy   2006 
jagadesh 4/m  3 R FH Triphasic r.nephroureterectomy CT&RT   
Jayaraman 2/m  1 R FH triphasic r.nephroureterectomy hemihypertrophy  2009 
jagan   1 L  triphasic r.nephroureterectomy   2003 
karthik 4/m  1 R FH triphasic r.nephroureterectomy    
kousalya 1/f  2 R FH triphasic r.nephroureterectomy    
kalaiselvi 1/f  2 L FH triphasic r.nephroureterectomy    
kavinraj 1/f 12.01.02 1 R FH triphasic r.nephroureterectomy   f/u3.08.08 
lavanya 6/f Nov-01 2 L FH triphasic l.nephroureterectomy 366277  f/u-2003 
mohaprabu 3months  3 L FH triphasic l.nephroureterectomy    
manojkum 5/m  3 L FH triphasic l.nephroureterectomy    
manirathnam   4/m  1 L FH triphasic l.nephroureterectomy    
malarvizhi 5months  2 R FH triphasic r.nephroureterectomy    
manimegalai  
1/f   2 L FH triphasic l.nephroureterectomy    
nandagopal    1/m  2 L FH triphasic l.nephroureterectomy    
nithya 9/f 5.1.99 2 L FH triphasic l.nephroureterectomy 264470   
Priya   2 R FH triphasic r.nephroureterectomy    
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priyadarshini   3 L FH triphasic l.nephroureterectomy    
prescila 3y6  3 L FH triphasic l.nephrouretectomy terectomy   
preethy 3y6  2 L FH triphasic l.nephroureterectomy    
sudhakar 4y6  2 L FH triphasic l.nephroureterectomy    
satyanarayan   3/m  2 R FH triphasic r.nephroureterectomy   2010-may 
Satish 3/m  3 R FH triphasic r.nephroureterectomy    
suresh 2/m  3 R FH triphasic r.nephroureterectomy CT&RT  May-10 
vijay 3/m  3 L FH triphasic l.nephroureterectomy CT&RT   
vimalraj 7months May-01 2 R FH triphasic r.nephroureterectomy half dosechemo   
vignesh 7/m   L FH triphasic l.nephroureterectomy    
vino 5/m  3 R FH triphasic r.nephroureterectomy    
vanitha 5/f Dec-00 4 R FH triphasic r.nephroureterectomy lung sec-mar.01  2003-well 
yuvarani 3/f   R FH triphasic r.nephroureterectomy    
naveenkumar   1y6m   L FH triphasic l.nephroureterectomy    
praveena 4/f  3 R FH tubullar r.nephroureterectomy    
chelladurai  1/m   3 L FH triphasic L.nephrourterectomy    
pushpakar 3/m May-02 3 L FH triphasic L.nephroureterectomy CT&RT ?cxr-sec 30.09.08 
aravind 2y6m 
f/u-
30.03.04 3 L FH triphasic l.nephroureterectomy    
ajitkumar 4/m 21.2.04 2 R FH triphasic r.nephroureterectomy    
archana 5/f 09.09.04 3 L FH triphasic l.nephrourreterectomy   Dec-09 
adinarayanan 7/m Mar-04 3 L FH triphasic l.nephroureterectomy CT&RT  Feb-10 
dilliprakash   1y3m 19.10.05 3 L FH triphasic L.nephroureterectomy CT&RT  Jan-09 
franciskennady  Jan-03 3 R FH triphasic r.nephroureterectomy CT&RT  Dec-09 
gowthami 5/f  3 R FH triphasic r.nephroureterectomy CT&RT  Apr-10 
Hemadevi   1y9m 23.03.04 2 R FH triphasic r.nephroureterectomy CT&RT  May-10 
ilakya 2/f 30.06.05 1 L FH triphasic l.nephroureterectomy defaulted   
Jayashree 1y6m 28.10.03 3 R FH triphasic r.nephroureterectomy CT&RT  Nov-09 
kavya 1y3m 2003 3 R FH epithelial r.nephroureterectomy CT&RT  Aug-09 
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Kumaran 3y6m 19.10.04 3 R FH triphasic r.nephroureterectomy CT&RT   
karthik 3/m jan.05 1 R FH triphasic r.nephroureterectomy CT&RT recurrence Sep-09 
karthik 4/m jan.05 2 R FH triphasic r.nephroureterectomy CT&RT  Oct-09 
lokesh 1O/M 21.06.05 2 R FH triphasic r.nephroureterectomy CT&RT   
sandya 4/f 2009 3 R FH triphasic r.nephroureterectomy CT&RT  Jun-09 
Manikandan     3/m 29.3.03 1 L FH triphasic L.nephroureterectomy   Nov-09 
Manikandan     3/m 19.1.04 2 L FH triphasic l.nephroureterectomy    
Meenakshi 6/F 27.03.04 3 L FH triphasic l.nephroureterectomy CT&RT  Jan-10 
nithya 9/f  3 R FH triphasic r.nephroureterectomy CT&RT   
dathathreyan   1y6m 2008 3 R FH triphasic r.nephroureterectomy   Dec-09 
Pooja 1Y1M 2008 1 L FH blastemal l.nephroureterectomy   Feb-10 
sindhu 5/m 2008 1 R FH epithelial r.nephroureterectomy   Apr-10 
reddiyama 5/f 2008 2 R FH triphasic r.nephroureterectomy CT&RT  Mar-10 
chandru 1y6m 2008 1 R FH triphasic r.nephroureterectomy   May-10 
dhanusha 4/f 2008 3 L FH triphasic l.nephroureterectomy CT&RT  Dec-09 
wahithabanu    4/f 2008 3 L FH triphasic l.nephroureterectomy   Nov-09 
abimanu 4/m 13.06.06 1 R FH triphasic r.nephroureterectomy   Jun-09 
Anitha 1y6m 3.04.07 5 b/l FH triphasic  CT&RT  lostf/u 
barath 10months 4.12.07 1 L FH triphasic l.nephroureterectomy   Aug-09 
Darshini 1y6m 10.07.07 1 R FH triphasic r.nephroureterectomy   May-10 
dinesh 10months 30.04.07 1 L FH triphasic l.nephroureterectomy   Apr-09 
dathatreyan    1y6m 24.01.08 3 R FH triphasic r.nephroureterectomy CT&RT   
gouthami 6/f Jun-04 3 R FH triphasic r.nephroureterectomy 
thrombus  not 
extracted  f/u-24.5.08 
ganesan 1y6m 26.06.06 3 R FH triphasic r.nephroureterectomy CT&RT  Sep-09 
gayathri 2y6m 11.07.06 3 L FH triphasic l.nephroureterectomy CT&RT  Oct-09 
harshavardan    4/m 10.06.06 2 R FH triphasic r.nephroureterectomy CT&RT  Jan-10 
kamesh 3y6m  3 R FH triphasic r.nephroureterectomy CT&RT  Jul-09 
kalaiselvan     6/m  3 L FH triphasic  CT&RT  lostf/u 
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monisha 4y6m  3 R FH triphasic r.nephroureterectomy CT&RT   
niranjan  Mar-06 3 R FH triphasic r.nephroureterectomy CT&RT  Feb-09 
parthiban 2y9m 19.01.06 3 L FH triphasic l.nephroureterectomy CT&RT  Aug-09 
purosathaman    5/m 18.07.06 1 R FH triphasic r.nephroureterectomy   Apr-10 
praveen 7/m  2 R FH triphasic r.nephroureterectomy CT&RT  Mar-10 
pooja 1/f 19.09.06 1 R FH triphasic r.nephroureterectomy    
pooja 11months 18.01.08 1 R FH triphasic r.nephroureterectomy    
Ravikumar 4/m 26.10.06 1 L FH triphasic L.nephroureterectomy   16.9.08 
tamilarasan 1y6m 30.12.06 2 R FH triphasic r.nephroureterectomy CT&RT   
tangamani 3/m 13.06.07 2 R FH triphasic r.nephroureterectomy local recurrence  lostf/u 
anish 11months 2008 1 L FH triphasic L.nephroureterectomy   Apr-10 
pavithra 2/f 2008 1 L FH triphasic L.nephroureterectomy cysticwilm  May-10 
mohanraj 3/m 2008 2 L FH triphasic L.nephroureterectomy CT&RT  Sep-09 
sudharsana 7/m 1.7.03 
3horse shoe 
kidney  FH triphasic L.nephroureterectomy tumour spill  f/u-23/5/06 
pushpakar 4y6m 2003 2 L FH triphasic L.nephroureterectomy CT&RT  Jul-09 
pavithra 2/f 2003 2 R FH triphasic r.nephroureterectomy CT&RT  Jun-09 
parthiban 1y6m 2003 1 L FH triphasic l.nephroureterectomy    
syedsulthana    5mon 2003 1 R FH triphasic r.nephroureterectomy    
sheela 4/f 2003 2 L FH triphasic L.nephroureterectomy ct&rt  Feb-20 
sharmila 3y6m 2004 1 R FH triphasic r.nephroureterectomy 522799 2008-well  
sundarrajan    8/m 2005 2 R UFH triphasic r.nephroureterectomy   lost f/u 
surya 5/m 2005 duplex-2 R FH triphasic r.heminephrectomy 446864 recurrence defaultedRT 
sakthivel 10months 2006 4 L FH triphasic L.nephroureterectomy   Oct-09 
Thirumalai 4/m 2006 2 L FH triphasic L.nephroureterectomy   Nov-09 
thirunavukarasu  9/m 2006 2 L FH triphasic L.nephroureterectomy   Jun-09 
thilani 5/f 2005 1 L FH triphasic L.nephroureterectomy   Sep-08 
thirumurugan  5/m 1.2.2006 3 R FH triphasic r.nephroureterectomy 524468 f/u9.9.08  
vasanthkumar   7/m Mar-06  L FH triphasic L.nephroureterectomy 506170  Sep-09 
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yuvaraj 1y6m Sep-06  L FH triphasic L.nephroureterectomy   Jan-10 
yasmin 4/f Apr-06  L FH triphasic L.nephroureterectomy   Apr-09 
hemadevi 1y9m 3.4.04 2 R FH triphasic r.nephroureterectomy   Feb-10 
lavanya 8/f 23.02.05 3 R FH triphasic r.nephroureterectomy 
lung RT-
givenf/u-15.7.08   
kaviarasan  1997  L FH triphasic L.nephroureterectomy  2008-well  
sangeetha   3 L FH triphasic L.nephroureterectomy 8yr-survival   
soubarnika  97  R FH triphasic r.nephroureterectomy 11yr-survival   
sathishkumar    R FH triphasic r.nephroureterectomy 15yr-survival   
Binnsajan 6/m 568257 2 L FH triphasic l.nephroureterectomy recurrence lung sec  
kamurunisha- 12/f  2 L FH triphasic l.nephroureterectomy hemihypertrophy  May-10 
muthumadhavan  6/m  duplex-3  FH triphasic l.nephroureterectomy    
thanusha 4/f  3 R FH triphasic 
atrial thrombus-partial 
thrombectomy    
kumaran 3y6m 473179 3 R FH triphasic l.nephroureterectomy thrombectomy  f/u2009-feb 
chaitanya 3/f  3 R FH triphasic tumor dissemination  neoadjuvani  
rohith 2/m  3 L FH triphasic l.nephroureterectomy biopsy death  
malarvizhi 5/f 674021 1 R FH triphasic r.nephroureterectomy hpe195/10   
deepika   3 L FH epithelial l.nephroureterectomy  neoadjuvant  
sudharsan 1y6m 672054  R FH triphasic r.nephroureterectomy    
deepak 2/m 674525  l FH triphasic l.nephroureterectomy    
sabarivasan- 2/m 673 2 l FH triphasic l.nephroureterectomy  
WAGR-
syndrome  
monisha 2/F 674101 4 R FH 
Rhabdomyo 
matous r.nephroureterectomy  neoadjuvant  
soundarya 6/f 673833 3 R FH 
Rhabdomy 
omatous r.nephroureterectomy ascites neoadjuvant  
aswathdevi 1y6m 676082 3 R FH 
Rabdomy 
omatous l.nephroureterectomy  neoadjuvant  
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jeganbabu 4M 664680  L FH  r.nephroureterectomy    
Harish 3y6m 658953 4 R FH triphasic r.nephroureterectomy lung sec death  
nivedha 3/F  2 L FH triphasic l.nephroureterectomy   Apr-10 
Alifa 9months  4 L UFH rhabdoid l.nephroureterectomy liver sec death  
senbagavel 3/m  3 R FH triphasic   neoadjuvant  
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DISCUSSION 
 This  is a retrospective  study  of   135  Wilms’ tumor  patients  & 
prospective  study  of   21  patients   from  2007   -   2010   . We have 
studied 99 male children &57 female children  with Wilms tumor.   We   
have studied   30  cases  of  stage-I   disease ,61 cases  of   stage  -II 
disease ,46  cases of stage -III  disease ,10  cases  of  stage -IV Wilms  ,  9  
cases of stage-V Wilms.  We had followed NWTS -5 protocol.  
 All   wilms  tumor patient  details  were  retrieved  from  tumor  
register  & medical  records department. 
 All  children   underwent  follow-up  screening with  Ultra 
sonogram,  CHEST  X-ray , urine  -   micro albumin estimation  , & blood  
pressure recordings . Plain x-ray of  chest to look  for  secondary in lungs 
.  CT  chest  was  done  in two  cases  which had   doubtful shadows  in  
chest  x-rays. 
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HISTOPATHOLOGY 
  Histopathology  of 156 patients showed  2 unfavorable  histology, 
154 showed favorable  histology[FH] ,which includes 145 triphasic  
histology  & 9 monophasic variety 
Stage-I Stage-II Stage-III Stage-IV Stage-v 
30 61 46 10 9 
27-triphasic   
3-monophasic 
57-triphasic, 
4-monophasic 
44-FH,2-
unfavorable 
histology 
8-triphasic, 
2-monophasic 
9-favorable 
histology 
 
 Only 2 out of 156 cases   were of   unfavorable histology. Both 
cases were in stage III.  
 ULTRASONOGRAM was done to look for liver metastasis . 
 Presence of   thrombus is picked  up   with   high  resolution   
ultrasound  in IVC &   atrium . They were serially   screened for its 
disappearance   with radiotherapy and chemotherapy.  It  takes   24  
weeks  to  two  years  for  the  tumor  thrombus  to resolve. We had 
six cases of tumor   thrombus. 4 cases of IVC thrombus   resolved 
with chemotherapy.   One out of 2 atrial   thrombus underwent    
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cardiac bypass and atrial thrombectomy . The other case of   atrial   
thrombus resolved with chemotherapy. 
 CT-contrast study was done in all bilateral tumor after chemo & 
RT to  look for residual lesion.  
 5   year survival  is  98%  in  stage 1 &  2.  Long  term  disease free  
survival over   10  years is seen   in 10 of   our  wilms  tumor patients. 
• Hypertension  was  present  in 1% after ten years.  
• We have had no second malignant neoplasm in our series.  
• Micro albuminuria was present in1% of long term survivors. 
• Their  skeletal  growth  was affected in two children in our series . 
•  Ionising radiation affects epiphyseal growth.soft tissue hypoplasia 
and diminished bone growth is followed by  scoliosis  our series of 
patients  had stunted growth but  no scoliosis 
• They  did  not  show  any  delay  in  sexual  maturity .  
• Damage  to the reproductive systems may represent one of the 
main late  sequelae of both,gonadal radiation or chemotherapeutic  
agents.  
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• Radiation effects even on prepubertal germ cells may lead to 
gonadal dysfunction. 
• Ovarian failure was seen in  75% of patients where the ovaries 
were included in radiation field in  Europian study series. 
•  Ovaries are not included  in radiation field  in  our centre. Hence 
we have not had ovarian failure in our series. 
• Normal ovarian follicles were seen in Ultra-sonogram done in long 
term survivors in our centre.  
• cardio toxicity  due to adriamycin was  not  seen in our series. 
 ECHO  was done in all stage III patients every year to rule out 
cardiotoxicity 
• Renal failure was noted in 2 of   our   bilateral   Wilms tumor  cases 
who  underwent  bilateral partial   nephrectomy.  
• We  have  had  radiation  enteritis  in  3  patients and  
• one patient  had    defaulted  RT  and  landed up with  bilateral lung  
secondaries. 
 
 
 54
OBSERVATION 
• All bilateral wilms  patients  were  under  7  years of age.   Stages I 
& II have good prognosis.  97 % of cases show   disease free 
survival status. Mortality  is  nil  in our study from1998 till  date in  
stages  I &II . 
• We  have  had 10  recurrences in  stage III .Heminephrectomy was 
done in one of double moiety and child was not given radiotherapy 
as child was  understaged   Salvage chemotherapy was not 
effective in these children . 
• Tumour spillage and defaulting chemotherapy or radiotherapy 
results in recurrences.In stage IV, 50% mortality was seen.  
Syndromic variety   tumors   do well   with surgery,  postoperative  
chemotherapy  & radiotherapy[RT].   Bilateral  Wilms  have bad  
prognosis .Life expectancy in bilateral wilms’ is  two years  from  
the  time  of  onset of    disease . 
• Neo-adjuvant chemotherapy reduces  recurrences &mortality in 
stage IV disease .Neo-adjuvant chemotherapy changes the 
histology of the tumour. 
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Stage 
Micro 
Albuminuria 
Cardiac 
status 
Skeletal 
growth 
Sexual 
maturity Hypertension 
I & II 2 N N No  delay N 
III 15 N N No  delay N 
IV RF: 2 N On F/U On F/U N 
V RF-2 CCF-2 Stunted-2 - N 
 
 Foot-note: RF-renal failure, CCF-congestive cardiac failure,F/U-
follow-up 
Infertility: 
 Alkylating  chemotherapeutic agents more often affect dividing 
cells and causing gonadal dysfunction. Vincristine  has been described as 
a major risk factor for azoospermia and it is temporary. Our series 
children are too young to  be checked.  
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RESULTS 
 Prognosis in wilms tumor   is  directly  dependant  on  the stage of   
disease .This emphasizes the need for  accurate  staging   before 
chemotherapy & radiotherapy .    Quality  of life   was well  preserved  in  
stages  -1,  2 &  3  disease. 
 Recurrences are  more  common  in  tumor  spillage and recurrent 
tumors have uniformly failed to respond to salvage regimen . Those 
children with advanced stage disease who responded favorably to chemo 
therapy & radiotherapy regime have survived beyond five years.The non-
responders of this group deteriorated  over the next five years.  
 We  have had follow-up  stage I & II  children   till  20 years of  
life  & observed  97% disease  free  survival status .We have followed  
stage III  children  upto 10 years  of  their  lives & observed  70% of 
disease free  survival status . 
 We  have  followed  stage IV Wilms  tumor  children  for  5  years 
& observed  50% mortality in our series .Stage V have  shown 2 years 
survival  from the onset  of  disease .  
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 Stages I & II have good prognosis.  97 % of cases show   disease 
free survival status. Mortality  is  nil  in our study from1998 till  date in  
stages  I &II. We  have  had 10  recurrences in  stage III. Salvage 
chemotherapy was not effective in these children. 
 In stage IV, 50% mortality was seen. 
 Syndromic variety   tumors   do well   with surgery,  postoperative  
chemotherapy  & radiotherapy[RT].   Bilateral  Wilms  have bad  
prognosis .Life expectancy in bilateral wilms’ is  two years  from  the  
time  of  onset of    disease .We had given neoadjuvant  chemotherapy for 
14 cases,9bilateral cases  5  large tumours,1ascites patient. 
Neo-adjuvant chemotherapy reduces  recurrences &mortality in 
stage IV disease. 
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CONCLUSION 
• Stage  I &II    have  good  prognosis . 
• Stage  III    &  IV   needs close  surveillance   since  they  have  
high  rate  of  recurrence.   Recurrent tumors   are not amenable to 
salvage chemotherapy. 
• Stage V have bad prognosis. 
• Stage IV  wilms  need lung irradiation. 
• Neoadjuvant chemotherapy reduces tumor spillage in stage III  
&IV. 
• Survival is poor in patients with wilms tumor and coexisting renal 
anomalies like horse shoe kidney 
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